Elias D. Rady
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Elias D. Rady has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Ahmad Anouti
Department of Pediatrics University of Texas Southwestern Medical Center Dallas Texas USA
4 shared publications - Thomas Gerard Cotter
Division of Digestive and Liver Diseases UT Southwestern Medical Center Dallas Texas USA
4 shared publications - Amal Aqul
Department of Pediatrics, UT Southwestern Medical Center in Dallas/Children's Health, Dallas, Texas, USA
1 shared publication Amit G Singal
Division of Digestive and Liver Diseases, UT Southwestern Medical Center, Dallas, TX, USA
1 shared publicationCourtney N Roberts
Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA
1 shared publicationCourtney N. Roberts
University of Texas Southwestern Medical School Dallas Texas USA
1 shared publication
Latest Publications
- Open Access
- 1 October 2026
- Published by Taylor & Francis in Risk Management and Healthcare Policy
- Vol. ume 19, 1-5
Racial and Ethnic Differences in Medical Mistrust Among Patients with Non-Decompensated ALD and MetALD
Alcohol-associated liver disease (ALD) is a leading cause of liver-related mortality and represents a growing healthcare and economic burden
- 1 October 2026
- Published by Taylor & Francis in Risk Management and Healthcare Policy
- Vol. ume 19, 1-5
Open AccessRacial and Ethnic Differences in Medical Mistrust Among Patients with Non-Decompensated ALD and MetALD
Alcohol-associated liver disease (ALD) is a leading cause of liver-related mortality and represents a growing healthcare and economic burden
- Open Access
- 1 February 2026
- Published by AME Publishing Company in Translational Pediatrics
- Vol. 15 (2) , 54
Prognostic biomarkers in Fontan associated liver disease
Fontan-associated liver disease (FALD) is a universal consequence of the Fontan circulation and a growing cause of morbidity. Clinical outcome stratification is difficult because conventional tests lack sensitivity. In this review, we aim to discuss current prognostic tools for FALD. Histology remains the reference standard, capturing the characteristic pericentral and bridging “reverse lobulation” pattern of fibrosis. However, the invasive nature of liver biopsy and susceptibility to sampling bias limit its use. Magnetic resonance elastography (MRE) provides whole-organ stiffness assessment with concurrent evaluation of splenomegaly and varices, yet stiffness thresholds are not standardized and may overestimate fibrosis in the setting of hepatic congestion. Serum and composite indices [e.g., aspartate aminotransferase to platelet ratio index (APRI), fibrosis-4 (FIB-4) index, Model for End-Stage Liver Disease excluding international normalized ratio (MELD-XI)] provide some limited prognostic information in FALD; however, there is a need for disease-specific models. Emerging work integrates imaging and laboratory data to build risk calculators such as the FALD and Fontan Liver Risk Score (FonLiver). Multicenter pediatric validation and outcome-based calibration remain major gaps. Future progress requires prospective, multicenter pediatric studies with harmonized imaging protocols and novel biomarkers. Such integration is essential to move FALD prognostication from descriptive observation toward predictive and ultimately preventative care, optimizing timing of intervention and associated transplant decisions for individuals living with Fontan circulation.
- 1 February 2026
- Published by AME Publishing Company in Translational Pediatrics
- Vol. 15 (2) , 54
Open AccessPrognostic biomarkers in Fontan associated liver disease
Fontan-associated liver disease (FALD) is a universal consequence of the Fontan circulation and a growing cause of morbidity. Clinical outcome stratification is difficult because conventional tests lack sensitivity. In this review, we aim to discuss current prognostic tools for FALD. Histology remains the reference standard, capturing the characteristic pericentral and bridging “reverse lobulation” pattern of fibrosis. However, the invasive nature of liver biopsy and susceptibility to sampling bias limit its use. Magnetic resonance elastography (MRE) provides whole-organ stiffness assessment with concurrent evaluation of splenomegaly and varices, yet stiffness thresholds are not standardized and may overestimate fibrosis in the setting of hepatic congestion. Serum and composite indices [e.g., aspartate aminotransferase to platelet ratio index (APRI), fibrosis-4 (FIB-4) index, Model for End-Stage Liver Disease excluding international normalized ratio (MELD-XI)] provide some limited prognostic information in FALD; however, there is a need for disease-specific models. Emerging work integrates imaging and laboratory data to build risk calculators such as the FALD and Fontan Liver Risk Score (FonLiver). Multicenter pediatric validation and outcome-based calibration remain major gaps. Future progress requires prospective, multicenter pediatric studies with harmonized imaging protocols and novel biomarkers. Such integration is essential to move FALD prognostication from descriptive observation toward predictive and ultimately preventative care, optimizing timing of intervention and associated transplant decisions for individuals living with Fontan circulation.
- Open Access
- 22 December 2025
- Published by Wiley in Liver International
- Vol. 46 (1) , e70489
Integrating Phosphatidylethanol to Enhance Alcohol Quantification in Steatotic Liver Disease and Clinical Trials
Accurate quantification of alcohol intake is essential for the diagnosis, subclassification, and management of steatotic liver disease (SLD). In everyday clinical practice, alcohol histories rely primarily on physician‐assisted self‐report, with validated questionnaires used variably. Both provider‐level inconsistencies in documentation and patient‐level factors (e.g., recall and social‐desirability biases) can contribute to misclassification of SLD subtypes. Phosphatidylethanol (PEth), a direct alcohol biomarker detectable for ~2–4 weeks, has emerged as a promising objective tool that can complement self‐report. Across diverse SLD populations, PEth consistently uncovers underreported alcohol use, sharpens subclassification, informs prognosis, and enables longitudinal monitoring to guide care. In liver transplantation, PEth supports documentation of abstinence and detection of relapse to enable timely intervention. This mini‐review synthesises current evidence on PEth in SLD, emphasises its value in both clinical and research settings, and outlines priorities for integrating PEth into structured care pathways and clinical trial design to improve outcomes and harmonise endpoints.
- 22 December 2025
- Published by Wiley in Liver International
- Vol. 46 (1) , e70489
Open AccessIntegrating Phosphatidylethanol to Enhance Alcohol Quantification in Steatotic Liver Disease and Clinical Trials
Accurate quantification of alcohol intake is essential for the diagnosis, subclassification, and management of steatotic liver disease (SLD). In everyday clinical practice, alcohol histories rely primarily on physician‐assisted self‐report, with validated questionnaires used variably. Both provider‐level inconsistencies in documentation and patient‐level factors (e.g., recall and social‐desirability biases) can contribute to misclassification of SLD subtypes. Phosphatidylethanol (PEth), a direct alcohol biomarker detectable for ~2–4 weeks, has emerged as a promising objective tool that can complement self‐report. Across diverse SLD populations, PEth consistently uncovers underreported alcohol use, sharpens subclassification, informs prognosis, and enables longitudinal monitoring to guide care. In liver transplantation, PEth supports documentation of abstinence and detection of relapse to enable timely intervention. This mini‐review synthesises current evidence on PEth in SLD, emphasises its value in both clinical and research settings, and outlines priorities for integrating PEth into structured care pathways and clinical trial design to improve outcomes and harmonise endpoints.
- 22 April 2025
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 61 (11) , 1836-1837
Letter: Addressing the Growing Disparities in Alcohol‐Associated Liver Disease—A Call for Equitable Healthcare Strategies: Authors' Reply
- 22 April 2025
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 61 (11) , 1836-1837
Letter: Addressing the Growing Disparities in Alcohol‐Associated Liver Disease—A Call for Equitable Healthcare Strategies: Authors' Reply
- 18 April 2025
- Published by Elsevier in The American Journal of Pathology
- Vol. 196 (1) , 182-191
Current Clinical Trials for Alcohol-Associated Hepatitis
- 18 April 2025
- Published by Elsevier in The American Journal of Pathology
- Vol. 196 (1) , 182-191
Current Clinical Trials for Alcohol-Associated Hepatitis